Aydah AlAwadhi, Consultant Medical Oncologist and Division Chair of Hematology and Oncology Department at Sheikh Shakbout Medical City, Abu Dhabi, shared a post on LinkedIn:
“ctDNA is no longer the future in oncology; it’s becoming the present.
In a phase III NEJM trial, ctDNA-guided adjuvant atezolizumab after cystectomy significantly improved outcomes in muscle-invasive bladder cancer.
- DFS doubled: 9.9 vs 4.8 months (HR 0.64)
- OS benefit: 32.8 vs 21.1 months
- Benefit seen by treating only ctDNA-positive patients
This study adds to the growing evidence supporting the potential role of ctDNA in detecting minimal residual disease, informing adjuvant treatment decisions, and reducing unnecessary therapy, highlighting its evolving impact in oncology.”
More posts featuring Aydah AlAwadhi.